NASDAQ: BONBon Natural Life Ltd Stock
$0.06+0.00 (+0%)
Updated Apr 21, 2025
BON Price
$0.06
Fair Value Price
N/A
Market Cap
$234.26k
52 Week Low
$0.05
52 Week High
$5.31
P/E
0.35x
P/B
0.01x
P/S
0.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.84M
Earnings
$398.17k
Gross Margin
29.8%
Operating Margin
4.41%
Profit Margin
1.7%
Debt to Equity
0.4
Operating Cash Flow
-$8M
Beta
0.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BON Overview
Bon Natural Life Limited manufactures functional active ingredients extracted from natural herb plants in China. Offerings include personal care ingredients (plant-extracted fragrance compounds sold to perfume and fragrance manufacturers), natural health supplements (bioactive food ingredient products used as food additives), and nutritional supplements. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BON's potential to beat the market
- BON doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Food
Industry Rating
B
BON
RankedUnranked of 49
RankedUnranked of 49
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.38 | A | |
| $6.48 | A | |
| $11.36 | A |
Be the first to know about important BON news, forecast changes, insider trades & much more!
BON News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BON was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BON is good value based on its earnings relative to its share price (0.35x), compared to the US market average (27.14x)
P/E vs Market Valuation
BON is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BON due diligence checks available for Premium users.
Valuation
BON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.35x
Industry
16.3x
Market
27.14x
BON is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BON is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.01x
Industry
1.94x
BON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BON's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BON's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BON's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$61.8M
Liabilities
$17.4M
Debt to equity
0.4
BON's short-term assets ($39.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BON's short-term assets ($39.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BON vs Food Stocks
Bon Natural Life Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.